Want to see BCLI full AI Analyst Report?
BCLI Stock Chart & Stats
$0.96
-$0.04(-4.00%)
At close: 4:00 PM EDT
$0.96
-$0.04(-4.00%)
Day’s Range― - ―
52-Week Range$0.46 - $1.69
Previous CloseN/A
Volume10.75K
Average Volume (3M)22.93K
Market Cap
$9.93M
Enterprise Value$11.95
Total Cash (Recent Filing)$15.00K
Total Debt (Recent Filing)$1.49M
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding11,034,775
10 Day Avg. Volume25,343
30 Day Avg. Volume22,935
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.73
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.07
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Advocacy And SupportThere is growing support for NurOwn's approval, driven by media coverage and independent advocacy, including a Citizens' Petition.
Regulatory ProgressThe P3b study in ALS has been cleared by FDA, and the company plans to conduct the study under the Special Protocol Assessment.
Bears Say
Capital NeedsBrainStorm reported a net loss and will need to raise additional capital to move forward with the P3b study of NurOwn.
Financial ChallengesThe company needs to raise capital and the delisting along with the sharp decline in the share price increases the risk of an incrementally dilutive financing.
Brainstorm Cell Therapeutics News
BCLI FAQ
What was Brainstorm Cell Therapeutics’s price range in the past 12 months?
Brainstorm Cell Therapeutics lowest stock price was $0.46 and its highest was $1.69 in the past 12 months.
What is Brainstorm Cell Therapeutics’s market cap?
Brainstorm Cell Therapeutics’s market cap is $9.93M.
When is Brainstorm Cell Therapeutics’s upcoming earnings report date?
Brainstorm Cell Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 14 days.
How were Brainstorm Cell Therapeutics’s earnings last quarter?
Brainstorm Cell Therapeutics released its earnings results on May 15, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Brainstorm Cell Therapeutics overvalued?
According to Wall Street analysts Brainstorm Cell Therapeutics’s price is currently Overvalued.
Does Brainstorm Cell Therapeutics pay dividends?
Brainstorm Cell Therapeutics does not currently pay dividends.
What is Brainstorm Cell Therapeutics’s EPS estimate?
Brainstorm Cell Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Brainstorm Cell Therapeutics have?
Brainstorm Cell Therapeutics has 11,034,775 shares outstanding.
What happened to Brainstorm Cell Therapeutics’s price movement after its last earnings report?
Brainstorm Cell Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Brainstorm Cell Therapeutics?
Currently, no hedge funds are holding shares in BCLI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company focused on developing autologous cell-based therapies for neurodegenerative diseases. The company’s core program has been NurOwn, an investigational therapy involving a patient’s own cells that are processed to produce neurotrophic factors, with a primary historical focus on amyotrophic lateral sclerosis (ALS).
Technical Analysis
AIM ImmunoTech
―
Alaunos Therapeutics
―
―
PharmaCyte Biotech
―
Cyclerion Therapeutics
―
Ownership Overview
28.36% Insiders
0.03% Mutual Funds
1.32% Other Institutional Investors
70.29% Public Companies and
Individual Investors